These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 26809126)
1. Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis. Taddio A; Cattalini M; Simonini G; Cimaz R Expert Rev Clin Immunol; 2016 Jun; 12(6):641-9. PubMed ID: 26809126 [TBL] [Abstract][Full Text] [Related]
3. Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy. Chi H; Teng J; Yang C; Su Y Immunotherapy; 2018 Sep; 10(12):1033-1039. PubMed ID: 30185135 [TBL] [Abstract][Full Text] [Related]
9. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA). Nassar-Sheikh Rashid A; Schonenberg-Meinema D; Bergkamp SC; Bakhlakh S; de Vries A; Rispens T; Kuijpers TW; Wolbink G; van den Berg JM Pediatr Rheumatol Online J; 2021 Apr; 19(1):59. PubMed ID: 33926495 [TBL] [Abstract][Full Text] [Related]
12. Pneumonia in children with juvenile idiopathic arthritis in Finland 1999-2014: a nationwide retrospective register linkage study. Salonen PH; Säilä H; Salonen JH; Linna M; Helminen M; Kauppi MJ Clin Exp Rheumatol; 2018; 36(3):502-507. PubMed ID: 29303705 [TBL] [Abstract][Full Text] [Related]
14. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]. de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652 [TBL] [Abstract][Full Text] [Related]
15. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Dekker L; Armbrust W; Rademaker CM; Prakken B; Kuis W; Wulffraat NM Clin Exp Rheumatol; 2004; 22(2):252-8. PubMed ID: 15083897 [TBL] [Abstract][Full Text] [Related]
16. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Nimmrich S; Horneff G Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050 [TBL] [Abstract][Full Text] [Related]
17. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314 [TBL] [Abstract][Full Text] [Related]
18. Disseminated Tuberculosis Resulting From Reinfection in a Pediatric Patient Sequentially Treated With Etanercept and Adalimumab. Guerrero-Laleona C; Calzada-Hernández J; Bustillo-Alonso M; Gil-Albarova J; Medrano-San Ildefonso M; Iglesias-Jiménez E; Noguera-Julian A Pediatr Infect Dis J; 2017 Jan; 36(1):109-110. PubMed ID: 27749657 [TBL] [Abstract][Full Text] [Related]
19. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Foeldvari I; Becker I; Horneff G Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824 [TBL] [Abstract][Full Text] [Related]